Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.

Last updated: March 1, 2025
Sponsor: Tanta University
Overall Status: Active - Recruiting

Phase

2

Condition

Gastrointestinal Diseases And Disorders

Inflammatory Bowel Disease

Crohn's Disease

Treatment

Pentoxifylline 400 MG

Clinical Study ID

NCT05575505
11/2022
  • Ages 18-75
  • All Genders

Study Summary

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa; however, the exact underlying mechanisms of UC remain poorly understood. Also, it is associated with high risk of colon cancer, so there is a continuous need for introducing new therapies that decrease progression, and hence better outcomes

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Both males and females will be included

  • Negative pregnancy test and effective contraception.

Exclusion

Exclusion Criteria:

  • Breastfeeding

  • Significant liver and kidney function abnormalities

  • Colorectal cancer patients

  • Patients with severe UC

  • Patients taking rectal or systemic steroids

  • Patients taking immunosuppressives or biological therapies

  • Addiction to alcohol and / or drugs

Study Design

Total Participants: 44
Treatment Group(s): 1
Primary Treatment: Pentoxifylline 400 MG
Phase: 2
Study Start date:
February 02, 2023
Estimated Completion Date:
February 28, 2026

Connect with a study center

  • Faculty of Medicine, Mansoura University

    Mansoura, 35511
    Egypt

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.